Navigation Links
CSHL team shows how loss of key protein promotes aggressive form of leukemia
Date:7/1/2010

Cold Spring Harbor, NY New research by scientists at Cold Spring Harbor Laboratory (CSHL) has illuminated in fine detail one of the genetic paths that leads to a particularly aggressive form of leukemia.

CSHL Professor Scott W. Lowe. Ph.D., an Investigator of the Howard Hughes Medical Institute, led a team of scientists who wanted to know more about how the absence of an important tumor-suppressing protein called p53 combines with another genetic "hit" in immature blood cells to give rise to acute myeloid leukemia, or AML. In experiments in living mice, the team discovered that if p53 is disabled in immature blood-cell "precursors" in which a mutation in a gene called Kras is also present, a built-in braking mechanism fails to engage and the cells proliferate out of control.

Mutations in p53, the gene that encodes the p53 "master tumor-suppressor" protein, had previously been associated with drug resistance and adverse outcome in AML. The mechanism, however, was a matter of conjecture prior to the new results, which are published in the July 1 issue of Genes & Development.

"Our team has shown how mutations in Kras and p53 act to reinforce one another to change the character of blood precursor cells, transforming them into cells that can renew themselves and thus proliferate indefinitely, somewhat as cancer stem cells are theorized to do," says Lowe.

Under normal conditions, the ability to self-renew is possessed only by stem cells. Once stem cells give birth to "daughter" cells, those cells commit to a developmental pathway, and to a process called differentiation, that ends in their maturation as cells of a specific type. Blood-cell precursors, which are the "daughters" of hematopoietic stem cells, or HSCs, can differentiate into various kinds of mature blood cells, which normally have a finite lifespan. Recently, p53 has been shown to enforce this program in healthy stem cells -- not only HSCs, but also breast and embryonic stem cells.

Graduate student Zhen Zhao, postdoctoral researcher Johannes Zuber, M.D., along with Lowe and others, hypothesized that loss of the p53 protein could impair the programmed cell fate and mortality of myeloid progenitors. "Although myeloid progenitors and their differentiated progeny normally lack self-renewal capabilities," explains Zhao, "these cells apparently acquire this ability during the course of leukemia development. How this happens is what we set out to discover."

Zhao and colleagues knew that mutations in Kras and other genes in the Ras signaling pathway can trigger replication stress in immature blood cells, in some instances calling p53 into action. That protein possesses a range of biological activities that are thought to contribute to its role in tumor suppression, including the ability to induce a cell to commit suicide (apoptosis) or to enter a quiescent state in which it can no longer multiply (senescence). When the p53 protein is missing or inactive, for instance due to a mutation in the gene that encodes it, a potentially vital element in a cell's "braking" system is disabled. Indeed, "mutational disruption of the p53 network is thought to occur in virtually all aggressive end-stage cancers," notes Zhao, although mutations are seen in only 10%-15% of AML cases at diagnosis. Those tend to be the cases most resistant to therapy and most likely to be lethal.

Using so-called mosaic mouse models, the Lowe lab recently demonstrated that p53 mutations could specifically confer resistance to chemotherapeutic agents used to treat AML in human patients. Zhao, Zuber and colleagues took advantage of these genetically hybrid mice and a technology called RNA interference, or RNAi. Using a short-hairpin RNA molecule, they inactivated the p53 gene in hematopoietic cells that also had mutations that made Kras oncogenic. Myeloid precursor cells with only the Kras mutation are proliferative, but not self-renewing. But the team observed that cells with oncogenic Kras combined with a p53 deficiency did acquire the capacity to indefinitely self-renew, and transform into leukemia-initiating cells.

"Mice with one or the other mutation do develop T-cell malignancies, albeit ones with long latencies," Zhao says. "But we showed how suppression of p53 cooperates with oncogenic Kras to promote AML of the treatment-resistant type. Importantly, we found that loss of p53, independently of oncogenic Kras activation, promotes the proliferation of myeloid progenitors." It is the combination of p53 loss and activation of oncogenic Kras that confers upon these cells the ability to continually self-renew and thus give rise to aggressive AML.

"In this work, we discovered a new tumor-suppressing function of p53, distinct, for instance, from apoptosis, and somewhat related to senescence," said Zuber. "We showed that it has the ability to reinforce cell-fate and differentiation programs. In AML, p53 loss leads to cancer by disabling this reinforcement. The question we are now eager to answer is whether p53 has similar functions in other types of cancer."


'/>"/>

Contact: Peter Tarr
tarr@cshl.edu
516-367-8455
Cold Spring Harbor Laboratory
Source:Eurekalert

Related biology news :

1. Flowering and freezing tolerance linked in wheat, study shows
2. Apples grow larger when cells dont divide, study shows
3. Study shows stability and utility of floating wind turbines
4. Same types of cell respond differently to stimulus, Stanford study shows
5. Soil-borne pathogens drive tree diversity in forests, study shows
6. Study shows adding UV light helps form Missing G of RNA building blocks
7. Suspended animation protects against lethal hypothermia, study shows
8. New online map shows network of protection for North Americas marine ecosystems
9. New psychological intervention program shows promise in helping those with bowel diseases
10. Stem-cell disruption induces skull deformity, UR study shows
11. Ultraviolet radiation not culprit killing amphibians, research shows
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/5/2016)... 2016 http://www.researchandmarkets.com/research/5kvw8m/global_facial ) ... "Global Facial Recognition Market 2016-2020" report ... ) has announced the addition of the ... report to their offering. --> ... announced the addition of the "Global ...
(Date:2/3/2016)... , Feb. 3, 2016 ... the addition of the "Emotion Detection ... Machine Learning, and Others), Software Tools (Facial ... Areas, End Users,and Regions - Global forecast ... --> http://www.researchandmarkets.com/research/d8zjcd/emotion_detection ) has ...
(Date:2/2/2016)... , Feb. 2, 2016   Parabon NanoLabs ... the U.S. Army Research Office and the Defense ... and sensitivity of the company,s Snapshot Kinship ... Mission and, more generally, defense-related DNA forensics.  Although ... capabilities (predicting appearance and ancestry from DNA evidence), ...
Breaking Biology News(10 mins):
(Date:2/9/2016)... ... , ... With a presidential election in November and the future of U.S. ... over 500 top healthcare leaders for a night and day of debates and discussions ... students of the University of Pennsylvania’s Wharton School, will be held February 18 – ...
(Date:2/9/2016)... ... February 08, 2016 , ... Net-Translators, an ... the launch of its revamped and improved website. In an on-going effort to ... redesigned website will better communicate how the company designs and delivers thorough, high-quality ...
(Date:2/9/2016)... ... 09, 2016 , ... The American Academy of Thermology (AAT) has ... 2016 AAT Member Certification Qualification Course for Technicians via a two part webinar on ... include a detailed review of hardware, software, and camera setup/operations, aligns with the in-person ...
(Date:2/9/2016)... , Feb. 9, 2016  DNAtrix, a ... for cancer, announced that its lead product, ... Commission as an orphan medicinal product for ... form of glioma, strikes approximately 25,000 people ... http://photos.prnewswire.com/prnh/20160208/330986LOGO --> ...
Breaking Biology Technology: